A detailed history of Fmr LLC transactions in Mannkind Corp stock. As of the latest transaction made, Fmr LLC holds 4,419,693 shares of MNKD stock, worth $29.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,419,693
Previous 4,415,147 0.1%
Holding current value
$29.6 Million
Previous $20 Million 15.35%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.05 - $5.43 $18,411 - $24,684
4,546 Added 0.1%
4,419,693 $23.1 Million
Q1 2024

May 13, 2024

SELL
$3.25 - $5.27 $4.96 Million - $8.04 Million
-1,525,736 Reduced 25.68%
4,415,147 $20 Million
Q4 2023

Feb 13, 2024

SELL
$3.34 - $4.29 $1.73 Million - $2.22 Million
-517,746 Reduced 8.02%
5,940,883 $21.6 Million
Q3 2023

Nov 13, 2023

BUY
$3.91 - $5.45 $4,547 - $6,338
1,163 Added 0.02%
6,458,629 $26.7 Million
Q2 2023

Aug 11, 2023

BUY
$3.72 - $4.79 $2,272 - $2,926
611 Added 0.01%
6,457,466 $26.3 Million
Q1 2023

May 11, 2023

SELL
$3.95 - $5.63 $6,395 - $9,114
-1,619 Reduced 0.03%
6,456,855 $26.5 Million
Q4 2022

Feb 13, 2023

SELL
$3.02 - $5.37 $400,995 - $713,028
-132,780 Reduced 2.01%
6,458,474 $34 Million
Q3 2022

Nov 10, 2022

BUY
$2.99 - $4.35 $15,727 - $22,880
5,260 Added 0.08%
6,591,254 $20.4 Million
Q2 2022

Aug 12, 2022

BUY
$2.67 - $4.77 $3.43 Million - $6.13 Million
1,284,286 Added 24.22%
6,585,994 $25.1 Million
Q1 2022

May 13, 2022

BUY
$2.62 - $4.45 $3,424 - $5,816
1,307 Added 0.02%
5,301,708 $19.5 Million
Q4 2021

Feb 14, 2022

BUY
$4.05 - $5.37 $3.45 Million - $4.58 Million
852,239 Added 19.16%
5,300,401 $23.2 Million
Q3 2021

Nov 15, 2021

BUY
$3.89 - $5.48 $6,566 - $9,250
1,688 Added 0.04%
4,448,162 $19.3 Million
Q2 2021

Aug 13, 2021

BUY
$3.61 - $5.45 $16.1 Million - $24.2 Million
4,446,474 New
4,446,474 $24.2 Million

Others Institutions Holding MNKD

About MANNKIND CORP


  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $1.72B
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track This Portfolio

Track Fmr LLC Portfolio

Follow Fmr LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.